Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Primaire auto-immuun hemolytische anemie geassocieerd met ischemisch CVA
feb 2024 | Benigne hematologie, Neuro-vasculair